Insulet Corporation (PODD)

Currency in USD
208.22
-9.89(-4.53%)
Closed·
208.21-0.01(0.00%)
·
Trading near 52-week Low
PODD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
208.14218.05
52 wk Range
208.14354.88
Key Statistics
Prev. Close
218.11
Open
216.83
Day's Range
208.14-218.05
52 wk Range
208.14-354.88
Volume
893.13K
Average Volume (3m)
990.33K
1-Year Change
-19.5285%
Book Value / Share
21.54
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PODD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
351.43
Upside
+68.78%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Insulet Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Corporation SWOT Analysis


Patch Pump Pionee
Insulet leads the insulin pump market with its innovative Omnipod 5 platform, boasting a $21.58 billion market cap and impressive 70.39% gross margins
Financial Triumph
Explore Insulet's record-breaking Q1 2025 performance, with 30% worldwide growth and raised 2025 revenue guidance to 19-22%, signaling strong market momentum
Market Expansion
Delve into Insulet's strategic moves in the Type 2 diabetes market and international expansion, unlocking vast growth potential in underpenetrated segments
Analyst Optimism
Discover why analysts project bullish price targets ranging from $266 to $365, reflecting confidence in Insulet's technological advancements and market position
Read full SWOT analysis

Insulet Corporation Earnings Call Summary for Q4/2025

  • Insulet's Q4 2025 revenue reached $784 million, exceeding forecasts with 29% growth in constant currency, while EPS of $1.44 slightly missed expectations.
  • The company's stock surged 7.98% in pre-market trading to $266, reflecting investor optimism despite the minor EPS miss.
  • For full-year 2025, Insulet achieved $2.7 billion in revenue (up 30.7%) with a gross margin of 71.6% and adjusted EPS of $4.97.
  • Management projects 21-23% Omnipod revenue growth for 2026, with plans to expand operating margins by 100 basis points and increase adjusted EPS by over 25%.
  • CEO Ashley McEvoy expressed confidence in the company's momentum, emphasizing 'Performance trumps everything' while highlighting upcoming product launches and market expansion.
Last Updated: 18/02/2026, 14:36
Read Full Transcript

Compare PODD to Peers and Sector

Metrics to compare
PODD
Peers
Sector
Relationship
P/E Ratio
59.3x3.2x−0.4x
PEG Ratio
−1.490.000.00
Price/Book
9.7x7.2x2.6x
Price / LTM Sales
5.4x4.1x3.1x
Upside (Analyst Target)
72.9%49.1%58.6%
Fair Value Upside
Unlock19.9%8.2%Unlock

Analyst Ratings

22 Buy
1 Hold
1 Sell
Ratings:
24 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 351.43
(+68.78% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Evercore ISI
Buy340.00+63.29%370.00Maintain19/02/2026
Bernstein SocGen Group
Buy330.00+58.49%380.00Maintain19/02/2026
Truist Securities
Buy360.00+72.89%390.00Maintain19/02/2026
JPMorgan
Buy340.00+63.29%415.00Maintain19/02/2026
Goldman Sachs
Buy326.00+56.57%363.00Maintain19/02/2026

Earnings

Latest Release
18/02/2026
EPS / Forecast
1.44 / 1.46
Revenue / Forecast
783.8M / 768.59M
EPS Revisions
Last 90 days

People Also Watch

52.46
ROL
-0.66%
284.93
CPAY
-2.82%
72.10
HSIC
-2.18%
81.91
VTR
-0.91%
80.85
EVRG
+0.56%

FAQ

What Is the Insulet (PODD) Share Price Today?

The Insulet stock price today is 208.22 USD.

What Stock Exchange Does Insulet (PODD) Trade On?

Insulet is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Insulet?

The stock symbol (also called a 'ticker') for Insulet is "PODD."

What Is the Current Insulet Market Cap?

As of today, Insulet market cap is 14.66B USD.

What Is Insulet's (PODD) Earnings Per Share (TTM)?

The Insulet EPS is currently 3.48 (Trailing Twelve Months).

When Is the Next Insulet Earnings Date?

Insulet's next earnings report will be released on 30/04/2026.

Is PODD a Buy or Sell From a Technical Analyst Perspective?

Based on today's Insulet moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Insulet Stock Split?

Insulet has split 0 times. (See the PODD stock split history page for full effective split date and price information.)

How Many Employees Does Insulet Have?

Insulet has 5400 employees.

What is the current trading status of Insulet (PODD)?

As of 28/03/2026, Insulet (PODD) is trading at a price of 208.22 USD, with a previous close of 218.11 USD. The stock has fluctuated within a day range of 208.14 USD to 218.05 USD, while its 52-week range spans from 208.14 USD to 354.88 USD.

What Is Insulet (PODD) Price Target According to Analysts?

The average 12-month price target for Insulet is 351.43 USD, with a high estimate of 435 USD and a low estimate of 286 USD. 22 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +68.78% Upside potential.

What Is the PODD Premarket Price?

PODD's last pre-market stock price is 219.27 USD. The pre-market share volume is 90.00, and the stock has decreased by 1.16, or 0.53%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.